DBVTFPNKHealthcare

DBV TECHNOLOGIES

Reports in 3d· 2026-04-30

-10.4% · 90d

$4.30

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for DBVTF will appear here as they are published.

Check back later for updates

Key Data

Market Cap$1.27B

Open$4.30

Prev Close$4.30

Day Range$4.30 – $4.30

52W Range$0.00 – $4.80

Volume100

P/E (TTM)—

EPS$-1.05

Dividend Yield—

Beta-0.20

Revenue Growth26.20%

Next Earnings2026-04-30(3d)

About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Healthcare · Biotechnology

www.dbv-technologies.com

Top Institutional Holders

As of 2025-03-31 · prior 2024-12-31

MORGAN STANLEY$464,019

616,801 sh+107.4%

See all holders →

Quarterly Financials

09/25

Revenue Net Income